Travere Therapeutics officer plans $121K share sale

The reported Rule 10b5-1 plan adoption or instruction date is May 29, 2025.

Accepted by SEC EDGAR 05/06/2026 - 09:37 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Travere Therapeutics, Inc. officer William E. Rote reported an intended sale of 2,763 common shares, with an aggregate market value of $121,433.85 and an approximate sale date of May 6, 2026. The shares were acquired from the issuer through restricted stock vesting on May 4, 2026, as compensation. Rote also reported selling 9,100 common shares on April 22, 2026, for gross proceeds of $355,719.

Key Figures

Shares intended for sale: 2,763 common shares Aggregate market value: $121,433.85 Shares sold: 9,100 common shares +3 more

6 metrics

Shares intended for sale 2,763 common shares Approximate sale date: May 6, 2026

Aggregate market value $121,433.85 Shares intended for sale

Shares sold 9,100 common shares April 22, 2026

Gross proceeds $355,719 Sale on April 22, 2026

Shares acquired through restricted stock vesting 2,763 shares May 4, 2026; compensation from the issuer

Rule 10b5-1 plan adoption or instruction date May 29, 2025 Date reported for reliance on Rule 10b5-1

Key Terms

Restricted Stock Vesting, Aggregate Market Value, Gross Proceeds, Rule 10b5-1

4 terms

Restricted Stock Vesting financial

"Nature of Acquisition Transaction: Restricted Stock Vesting"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

Aggregate Market Value financial

"Number of Shares or Other Units To Be Sold | Aggregate Market Value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Gross Proceeds financial

"Amount of Securities Sold | Gross Proceeds"

The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.

Rule 10b5-1 regulatory

"Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TVTX shares is William E. Rote proposing to sell?

Rote reported an intended sale of 2,763 common shares, with an aggregate market value of $121,433.85 and an approximate sale date of May 6, 2026.

How many TVTX shares did William E. Rote sell in April 2026?

Rote reported selling 9,100 common shares on April 22, 2026, for gross proceeds of $355,719.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001698262
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Travere Therapeutics, Inc.
SEC File Number	001-36257
Address of Issuer	3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CALIFORNIA 92130
Phone	888-969-7879
Name of Person for Whose Account the Securities are To Be Sold	ROTE WILLIAM E.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	2763	121433.85	92992905	05/06/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/04/2026	Restricted Stock Vesting	Issuer			2763	05/04/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
William E. Rote 3611 Valley Centre Drive Suite 300 San Diego CA 92130	Common	04/22/2026	9100	355719.00

144: Remarks and Signature

Remarks
Date of Notice	05/06/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/29/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Eric Janiak, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for William E. Rote
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)